Article

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19

2022-10-28

Abstract excerpt

High interleukin (IL)-6 levels are associated with more severe clinical manifestations in patients hospitalized with COVID-19, but the complex role of IL-6 in antiviral and inflammatory processes has made it difficult to decipher its involvement in the disease. IL-6 receptor blockade by tocilizumab (anti-IL6R; Actemra) is used globally for the treatment of severe COVID-19, yet a molecular understanding of the ther...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b8f6f660-c329-5c58-8e7c-d69cb2a8a30c
DOI: 10.1101/2022.10.27.514096

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19DOI 10.1101/2022.10.27.514096Read

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read

A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signalingSemantic proximity Read

A multimodal atlas of COVID-19 severity identifies hallmarks of dysregulated immunitySemantic proximity Read

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome.Semantic proximity Read

A meta-summary and bioinformatic analysis identified interleukin 6 as a master regulator of COVID-19 severity biomarkersSemantic proximity Read

Single-Cell Omics Reveals Dyssynchrony of the Innate and Adaptive Immune System in Progressive COVID-19Semantic proximity Read

Single-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammationSemantic proximity Read

Specialized interferon action in COVID-19Semantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read

A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19Semantic proximity Read

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity Read